A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdw659
Abstract: Background This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively). Patients and methods… read more here.
Keywords: patients cohort; cohort; anti pdgfr; pdgfr monoclonal ... See more keywords
Specific enterotype of gut microbiota predicted clinical effect of methotrexate in patients with rheumatoid arthritis.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac458
Abstract: OBJECTIVE The most used drug in rheumatoid arthritis (RA) remains methotrexate (MTX). Unfortunately, up to 50% of patients do not achieve a clinically adequate outcome. Here we study whether the gut microbiota patterns can aid… read more here.
Keywords: patients cohort; rheumatoid arthritis; microbiota; gut microbiota ... See more keywords
Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000029108
Abstract: Abstract The high-dose glucocorticosteroid (GC) treatment is the first choice for dermatomyositis complicated with interstitial lung disease (DM-ILD) but patients are resistant to the high-dose GC monotherapy. Besides, the high dose of GC, the secondary… read more here.
Keywords: day; patients cohort; severe conditions; interstitial lung ... See more keywords
Effects of Tocilizumab in COVID-19 patients: a cohort study
Sign Up to like & getrecommendations! Published in 2020 at "BMC Infectious Diseases"
DOI: 10.1186/s12879-020-05701-4
Abstract: Background Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with… read more here.
Keywords: covid patients; patients cohort; effects tocilizumab; study ... See more keywords